机器人辅助根治性膀胱切除加原位新膀胱重建:男性技术与功能结局
基于多中心数据库732例男性膀胱癌患者,分析机器人辅助根治性膀胱切除加体内原位新膀胱重建后12个月尿控与勃起功能。日间尿控率86%、夜间66%,勃起功能率55%;新膀胱类型与尿控无关,单侧或双侧保留神经与勃起功能正相关,年龄和ASA评分3与勃起功能负相关。
要点
- 术后12个月日间尿控率86%、夜间66%,含使用安全垫者分别为20%和32%。
- 术后12个月勃起功能率55%,含使用磷酸二酯酶5抑制剂助勃者24%。
- 单侧或双侧保留神经与勃起功能正相关,年龄和ASA评分3与勃起功能负相关。
核心结论
- 机器人辅助根治性膀胱切除加体内原位新膀胱重建在尿控方面通常与良好的功能结局相关。
- 勃起功能高度受神经保留程度、年龄和合并症影响。
研究设计与样本
- 研究采用多中心数据库,纳入因膀胱癌行机器人辅助根治性膀胱切除加体内原位新膀胱重建的男性患者732例,诊断时中位年龄64岁(四分位距58-70)。
- 新膀胱重建技术由医生酌情选择,包括Studer/Wiklund、S pouch、Gaston、vescica ileale Padovana或Hautmann技术。
主要发现
- 12个月尿控率日间为86%、夜间为66%,包括报告使用安全垫者(分别为20%和32%)。
- 12个月勃起功能率为55%,包括报告使用磷酸二酯酶5抑制剂助勃者(24%)。
- 校正潜在混杂因素后,新膀胱类型与尿控无关。
- 单侧保留神经与勃起功能正相关(OR 3.85,95%CI 1.88-7.85;p < 0.001),双侧保留神经与勃起功能正相关(OR 6.25,95%CI 3.55-11.0;p < 0.001)。
- 年龄与勃起功能负相关(OR 0.93,95%CI 0.91-0.95;p < 0.001),美国麻醉医师协会评分3与勃起功能负相关(OR 0.46,95%CI 0.25-0.89;p < 0.02)。
关键数值与推荐
- 新膀胱重建技术分布:Studer/Wiklund 74%、S pouch 1.5%、Gaston 19%、vescica ileale Padovana 1.5%、Hautmann 4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known regarding functional outcomes after robot-assisted radical cystectomy (RARC) and intracorporeal neobladder (ICNB) reconstruction. OBJECTIVE: To report on urinary continence (UC) and erectile function (EF) at 12 mo after RARC and ICNB reconstruction and investigate predictors of these outcomes. DESIGN, SETTING, AND PARTICIPANTS: We used data from a multi-institutional database of patients who underwent RARC and ICNB reconstruction for bladder cancer. SURGICAL PROCEDURE: The cystoprostatectomy sensu stricto followed the conventional steps. ICNB reconstruction was performed at the physician's discretion according to the Studer/Wiklund, S pouch, Gaston, vescica ileale Padovana, or Hautmann technique. The techniques are detailed in the video accompanying the article. MEASUREMENTS: The outcomes measured were UC and EF at 12 mo. RESULTS AND LIMITATIONS: A total of 732 male patients were identified with a median age at diagnosis of 64 yr (interquartile range 58-70). The ICNB reconstruction technique was Studer/Wiklund in 74%, S pouch in 1.5%, Gaston in 19%, vescica ileale Padovana in 1.5%, and Hautmann in 4% of cases. The 12-mo UC rate was 86% for daytime and 66% for nighttime continence, including patients who reported the use of a safety pad (20% and 32%, respectively). The 12-mo EF rate was 55%, including men who reported potency with the aid of phosphodiesterase type 5 inhibitors (24%). After adjusting for potential confounders, neobladder type was not associated with UC. Unilateral nerve-sparing (odds ratio [OR] 3.85, 95% confidence interval [CI] 1.88-7.85; p < 0.001) and bilateral nerve-sparing (OR 6.25, 95% CI 3.55-11.0; p < 0.001), were positively associated with EF, whereas age (OR 0.93, 95% CI 0.91-0.95; p < 0.001) and an American Society of Anesthesiologists score of 3 (OR 0.46, 95% CI 0.25-0.89; p < 0.02) were inversely associated with EF. CONCLUSIONS: RARC and ICNB reconstruction are generally associated with good functional outcomes in terms of UC. EF is highly affected by the degree of nerve preservation, age, and comorbidities. PATIENT SUMMARY: We investigated functional outcomes after robot-assisted removal of the bladder in terms of urinary continence and erectile function. We found that, in general, patients have relatively good functional outcomes at 12 months after surgery.
引用
- Martini A, Falagario UG, Russo A, et al. Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males. Eur Urol. 2023. PMID: 37117109. doi:10.1016/j.eururo.2023.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。